Regenerative Research Group
A physician-directed annual longevity program integrating three biologic preparation classes within a defined schedule of administration, clinical oversight, and reassessment.
The Program
The Longevity Program is a twelve-month, physician-directed framework for individuals pursuing a structured and proactive approach to long-term health, resilience, and healthy aging.
Three biologic preparation classes are integrated within a defined annual schedule, allowing the supervising physician to select the appropriate protocol, establish administration intervals, monitor clinical considerations, and modify the program as appropriate over time.
Designed around continuity rather than a single intervention, the program provides a structured annual framework while preserving individualized physician judgment throughout the year.
Program at a glance
Not intended to diagnose, treat, cure, or prevent disease. No preparation described here is represented as having FDA approval for a longevity indication. Participation is elective, individual results may vary, and all clinical decisions remain under the direction of the supervising physician.
Program Components
Preparation characteristics are presented by class, concentration, route, and protocol use.
Cryopreserved perinatal tissue matrix preparation
Secretome preparation with characterized growth factor content
Extracellular vesicle preparation with higher particle concentration
4 scheduled administration visits
The Foundational Protocol distributes three preparation classes across four scheduled administration visits during the twelve-month program. EXM is administered in Months 1 and 7. EXS is administered quarterly at 6 mL in Months 1, 4, 7, and 10. EXO-NEURAL is administered intranasally in Month 1.
Month of administration
Month 1 begins with the initial administration rather than the calendar year. Administration dates and intervals may be modified by the supervising physician based on individual clinical considerations.
Not intended to diagnose, treat, cure, or prevent disease. No preparation described here is represented as having FDA approval for a longevity indication. Participation is elective, individual results may vary, and all clinical decisions remain under the direction of the supervising physician.
6 scheduled administration visits
The Enhanced Protocol increases administration frequency across the twelve-month program. EXM is administered in Months 1, 5, and 9. EXS is administered every other month at 3 mL, for six administrations across the year. EXO-NEURAL is administered intranasally in Months 1 and 7.
Month of administration
The Enhanced Protocol emphasizes more frequent administration across the year. Protocol selection remains subject to individual physician assessment and clinical discretion.
Not intended to diagnose, treat, cure, or prevent disease. No preparation described here is represented as having FDA approval for a longevity indication. Participation is elective, individual results may vary, and all clinical decisions remain under the direction of the supervising physician.
Scientific Context
The biologic preparation classes incorporated into this program are associated with areas of active research involving mesenchymal stromal cells, secreted signaling factors, and extracellular vesicles.
How to read this section
The literature summarized here includes preclinical research, animal models, reviews, and early human studies, much of it in patients with diagnosed conditions rather than healthy adults pursuing longevity-oriented care. The published literature does not evaluate the exact annual schedules described here, in this population, or for this purpose. It is presented as scientific context regarding biological plausibility, observed mechanisms, and reported safety findings within the settings studied — it does not establish safety or effectiveness of these protocols or predict an individual outcome.
Research into healthy aging increasingly examines cellular senescence, intercellular signaling, oxidative stress, mitochondrial function, and the chronic low-grade inflammatory environment associated with aging, often described as inflammaging.
World Journal of Stem Cells, 2025
An experimental study evaluating mesenchymal stromal cell-derived extracellular vesicles in cellular and animal models of senescence, including vesicle characterization and in vitro and in vivo assessment of senescence-associated outcomes.
In vitro + animal studyFrontiers in Aging, 2026
A review of stem cell derived vesicles in aging biology, describing anti-inflammatory signaling across models of arthritis, sepsis, cardiovascular and neurological disease, and the transfer of mitochondrial material between cells under oxidative stress.
ReviewJournal of Extracellular Vesicles, 2024
A systematic review and meta-analysis of human extracellular vesicle-based therapies reported low rates of serious adverse events across included studies, while emphasizing substantial heterogeneity in product manufacturing, study design, and adverse-event reporting.
Systematic review + meta-analysisOsteoarthritis represents one of the more extensively studied musculoskeletal applications within extracellular vesicle and mesenchymal stromal cell research and includes emerging human clinical data.
Journal of Translational Medicine, 2025
Umbilical cord derived exosomes were tested first in cell culture and a mouse model, then in a randomized, double blind, ascending dose study in patients with knee osteoarthritis. The authors reported no adverse consequences and some degree of change in clinical scores and MRI findings.
Randomized human studyJournal of Cellular and Molecular Medicine, 2021
Exosomes maintained the cartilage cell phenotype by increasing type two collagen synthesis and reducing inflammation driven senescence and apoptosis, with a specific long noncoding RNA identified as partly responsible.
In vitro + animal modelInternational Journal of Molecular Sciences, 2025
Vesicles from three tissue sources were compared for cartilage protective effect. All showed low cytotoxicity and suppressed inflammatory markers, with bone marrow and umbilical cord sources performing more strongly than adipose.
In vitro + ex vivoThe intranasal route is an area of active neurological research because it has been investigated as a potential means of facilitating nose-to-brain transport through pathways associated with the olfactory and trigeminal systems.
Stem Cells Translational Medicine, 2020
Vesicles from preconditioned mesenchymal stem cells were given intranasally in a triple transgenic Alzheimer model. The material reached the brain and produced immunomodulatory and neuroprotective effects, with a higher density of dendritic spines in treated animals.
Animal modelStem Cells, 2021
A review of preclinical research involving intranasal delivery of mesenchymal stem cell-derived extracellular vesicles for neurological disease, including proposed nose-to-brain transport pathways, brain distribution, and outstanding questions regarding dose and biodistribution.
ReviewInternational Immunopharmacology, 2021
Intranasally administered mesenchymal stem cell-derived small extracellular vesicles were evaluated in an experimental neurological disease model. Treatment was associated with changes in clinical scores, central nervous system histology, and immunomodulatory responses.
Animal modelNot intended to diagnose, treat, cure, or prevent disease. No preparation described here is represented as having FDA approval for a longevity indication. Participation is elective, individual results may vary, and all clinical decisions remain under the direction of the supervising physician.
Clinical Governance
Participation should follow physician review of the individual's medical history, current health status, baseline clinical information, potential contraindications, concurrent medications or therapies, and any findings requiring additional evaluation.
The protocols described here provide a structured annual framework rather than an individualized medical prescription. Preparation selection, dosing, administration route, scheduling, reassessment, modification, continuation, and discontinuation remain within the clinical judgment of the supervising physician.
Before proceeding, patients should complete an informed consent process addressing potential risks, uncertainties, alternatives, and expected follow-up. Clinical findings or changes in health status may warrant modification or discontinuation of the program at any time.
No specific clinical outcome is represented, guaranteed, or implied by participation in the program.
Physician oversight
All administrations are performed or supervised under the direction of an appropriately licensed physician. The treating physician retains responsibility for determining whether participation is appropriate for the individual patient.
Not intended to diagnose, treat, cure, or prevent disease. No preparation described here is represented as having FDA approval for a longevity indication. Participation is elective, individual results may vary, and all clinical decisions remain under the direction of the supervising physician.
Selected Scientific References
References are provided for scientific context and do not constitute evidence supporting the specific program schedules described here.